Breaking Short Interest: What’s Ahead for Zosano Pharma Corporation (NASDAQ:ZSAN) After More Shorted Shares?

November 22, 2016 - By Ellis Scott   ·   0 Comments

Breaking Short Interest: What’s Ahead for Zosano Pharma Corporation (NASDAQ:ZSAN) After More Shorted Shares?

The stock of Zosano Pharma Corporation (NASDAQ:ZSAN) registered an increase of 40.84% in short interest. ZSAN’s total short interest was 311,400 shares in November as published by FINRA. Its up 40.84% from 221,100 shares, reported previously. With 39,300 shares average volume, it will take short sellers 8 days to cover their ZSAN’s short positions. The short interest to Zosano Pharma Corporation’s float is 4.34%. About 74,840 shares traded hands. Zosano Pharma Corp (NASDAQ:ZSAN) has declined 66.18% since April 20, 2016 and is downtrending. It has underperformed by 70.73% the S&P500.

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The company has a market cap of $12.22 million. The Firm has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. It currently has negative earnings. The Company’s microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Zosano Pharma Corp (NASDAQ:ZSAN) Ratings Coverage

Out of 3 analysts covering Zosano Pharma (NASDAQ:ZSAN), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Zosano Pharma has been the topic of 5 analyst reports since September 29, 2015 according to StockzIntelligence Inc. TH Capital maintained the stock with “Buy” rating in Wednesday, November 11 report. The stock has “Buy” rating given by Roth Capital on Wednesday, November 11. The firm has “Neutral” rating given on Thursday, August 11 by Ladenburg Thalmann. TH Capital maintained Zosano Pharma Corp (NASDAQ:ZSAN) on Tuesday, September 29 with “Buy” rating. Roth Capital maintained Zosano Pharma Corp (NASDAQ:ZSAN) rating on Tuesday, September 29. Roth Capital has “Buy” rating and $11 price target.

ZSAN Company Profile

Zosano Pharma Corporation, incorporated on January 26, 2012, is a clinical-stage specialty pharmaceutical company. The Firm has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. The Company’s microneedle patch system offers consistent drug delivery, and improved ease of use and room-temperature stability. The Company’s microneedle patch system has the potential to deliver various medications for a range of indications in commercially attractive markets.

Another recent and important Zosano Pharma Corp (NASDAQ:ZSAN) news was published by Marketwatch.com which published an article titled: “Zosano Pharma downgraded to neutral from buy at Ladenburg Thalmann” on August 03, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ellis Scott


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>